Limits...
Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure.

Yin M, Silljé HH, Meissner M, van Gilst WH, de Boer RA - Cardiovasc Diabetol (2011)

Bottom Line: Recently, glucagon-like peptide (GLP)-1 was shown to have cardioprotective effects, but treatment with GLP-1 is limited by its short half-life.Cardiac function (ejection fraction) was decreased in all 3 MI groups compared with Sham group (p < 0.05); treatment with vildagliptin, either early or late, did not reverse cardiac remodeling.Vildagliptin increases the active GLP-1 level via inhibition of DPP-4, but it has no substantial protective effects on cardiac function in this well established long-term post-MI cardiac remodeling model.

View Article: PubMed Central - HTML - PubMed

Affiliation: University Medical Center Groningen, University of Groningen, Department of Cardiology, Groningen, The Netherlands.

ABSTRACT

Background: Progressive remodeling after myocardial infarction (MI) is a leading cause of morbidity and mortality. Recently, glucagon-like peptide (GLP)-1 was shown to have cardioprotective effects, but treatment with GLP-1 is limited by its short half-life. It is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4), an enzyme which inhibits GLP-1 activity. We hypothesized that the DPP-4 inhibitor vildagliptin will increase levels of GLP-1 and may exert protective effects on cardiac function after MI.

Methods: Sprague-Dawley rats were either subjected to coronary ligation to induce MI and left ventricular (LV) remodeling, or sham operation. Parts of the rats with an MI were pre-treated for 2 days with the DPP-4 inhibitor vildagliptin (MI-Vildagliptin immediate, MI-VI, 15 mg/kg/day). The remainder of the rats was, three weeks after coronary artery ligation, subjected to treatment with DPP-4 inhibitor vildagliptin (MI-Vildagliptin Late, MI-VL) or control (MI). At 12 weeks, echocardiography and invasive hemodynamics were measured and molecular analysis and immunohistochemistry were performed.

Results: Vildagliptin inhibited the DPP-4 enzymatic activity by almost 70% and increased active GLP-1 levels by about 3-fold in plasma in both treated groups (p < 0.05 vs. non-treated groups). Cardiac function (ejection fraction) was decreased in all 3 MI groups compared with Sham group (p < 0.05); treatment with vildagliptin, either early or late, did not reverse cardiac remodeling. ANP (atrial natriuretic peptide) and BNP (brain natriuretic peptide) mRNA levels were significantly increased in all 3 MI groups, but no significant reductions were observed in both vildagliptin groups. Vildagliptin also did not change cardiomyocyte size or capillary density after MI. No effects were detected on glucose level and body weight in the post-MI remodeling model.

Conclusion: Vildagliptin increases the active GLP-1 level via inhibition of DPP-4, but it has no substantial protective effects on cardiac function in this well established long-term post-MI cardiac remodeling model.

Show MeSH

Related in: MedlinePlus

Effects of Vildagliptin on infarct size. A: Sirius red and fast green staining of rat myocardium shows the infarcted area with the red color in all groups. B:Graphic representation of infarct size expressed as percentage of the scar length to the total LV circumference. Data are presented as means ±SEM. N = 8-10 for all groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3198901&req=5

Figure 2: Effects of Vildagliptin on infarct size. A: Sirius red and fast green staining of rat myocardium shows the infarcted area with the red color in all groups. B:Graphic representation of infarct size expressed as percentage of the scar length to the total LV circumference. Data are presented as means ±SEM. N = 8-10 for all groups.

Mentions: Body weight (BW), LV weight (LVW) to body weight ratios (LVW/BW) and infarct sizes are shown in Table 1A. Ligation of the left coronary artery resulted in an infarct size of 47 ± 2% in control-treated MI group (Figure 2B). Although there was no significant reduction in the infarct size, vildagliptin treatment (both immediate and late) was associated with a trend towards smaller infarct size over the 3-month period of treatment compared with the MI control group (Figure 2B). There was no difference in body weight between groups both at baseline and at 12 weeks after MI surgery. The LVW/BW ratios in all MI groups were significantly increased compared to LVW/BW of the sham-operated group, however, LV hypertrophy was not significantly reduced by vildagliptin treatment (both groups) compared to MI control (Table 1A).


Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure.

Yin M, Silljé HH, Meissner M, van Gilst WH, de Boer RA - Cardiovasc Diabetol (2011)

Effects of Vildagliptin on infarct size. A: Sirius red and fast green staining of rat myocardium shows the infarcted area with the red color in all groups. B:Graphic representation of infarct size expressed as percentage of the scar length to the total LV circumference. Data are presented as means ±SEM. N = 8-10 for all groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3198901&req=5

Figure 2: Effects of Vildagliptin on infarct size. A: Sirius red and fast green staining of rat myocardium shows the infarcted area with the red color in all groups. B:Graphic representation of infarct size expressed as percentage of the scar length to the total LV circumference. Data are presented as means ±SEM. N = 8-10 for all groups.
Mentions: Body weight (BW), LV weight (LVW) to body weight ratios (LVW/BW) and infarct sizes are shown in Table 1A. Ligation of the left coronary artery resulted in an infarct size of 47 ± 2% in control-treated MI group (Figure 2B). Although there was no significant reduction in the infarct size, vildagliptin treatment (both immediate and late) was associated with a trend towards smaller infarct size over the 3-month period of treatment compared with the MI control group (Figure 2B). There was no difference in body weight between groups both at baseline and at 12 weeks after MI surgery. The LVW/BW ratios in all MI groups were significantly increased compared to LVW/BW of the sham-operated group, however, LV hypertrophy was not significantly reduced by vildagliptin treatment (both groups) compared to MI control (Table 1A).

Bottom Line: Recently, glucagon-like peptide (GLP)-1 was shown to have cardioprotective effects, but treatment with GLP-1 is limited by its short half-life.Cardiac function (ejection fraction) was decreased in all 3 MI groups compared with Sham group (p < 0.05); treatment with vildagliptin, either early or late, did not reverse cardiac remodeling.Vildagliptin increases the active GLP-1 level via inhibition of DPP-4, but it has no substantial protective effects on cardiac function in this well established long-term post-MI cardiac remodeling model.

View Article: PubMed Central - HTML - PubMed

Affiliation: University Medical Center Groningen, University of Groningen, Department of Cardiology, Groningen, The Netherlands.

ABSTRACT

Background: Progressive remodeling after myocardial infarction (MI) is a leading cause of morbidity and mortality. Recently, glucagon-like peptide (GLP)-1 was shown to have cardioprotective effects, but treatment with GLP-1 is limited by its short half-life. It is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4), an enzyme which inhibits GLP-1 activity. We hypothesized that the DPP-4 inhibitor vildagliptin will increase levels of GLP-1 and may exert protective effects on cardiac function after MI.

Methods: Sprague-Dawley rats were either subjected to coronary ligation to induce MI and left ventricular (LV) remodeling, or sham operation. Parts of the rats with an MI were pre-treated for 2 days with the DPP-4 inhibitor vildagliptin (MI-Vildagliptin immediate, MI-VI, 15 mg/kg/day). The remainder of the rats was, three weeks after coronary artery ligation, subjected to treatment with DPP-4 inhibitor vildagliptin (MI-Vildagliptin Late, MI-VL) or control (MI). At 12 weeks, echocardiography and invasive hemodynamics were measured and molecular analysis and immunohistochemistry were performed.

Results: Vildagliptin inhibited the DPP-4 enzymatic activity by almost 70% and increased active GLP-1 levels by about 3-fold in plasma in both treated groups (p < 0.05 vs. non-treated groups). Cardiac function (ejection fraction) was decreased in all 3 MI groups compared with Sham group (p < 0.05); treatment with vildagliptin, either early or late, did not reverse cardiac remodeling. ANP (atrial natriuretic peptide) and BNP (brain natriuretic peptide) mRNA levels were significantly increased in all 3 MI groups, but no significant reductions were observed in both vildagliptin groups. Vildagliptin also did not change cardiomyocyte size or capillary density after MI. No effects were detected on glucose level and body weight in the post-MI remodeling model.

Conclusion: Vildagliptin increases the active GLP-1 level via inhibition of DPP-4, but it has no substantial protective effects on cardiac function in this well established long-term post-MI cardiac remodeling model.

Show MeSH
Related in: MedlinePlus